K36 Therapeutics

K36 Therapeutics is a private biotechnology company developing breakthrough therapies for unmet medical needs in cancer patients. We are developing KTX-1001 to provide a targeted treatment specifically addressing the underlying cause of cancer in these multiple myeloma patients. KTX-1001 will be the first therapeutic agent to enter clinical trials directly targeting MMSET overexpression.